Anti-PD-1-IL-18 antibody(Fuse BioTherapeutics)(Anti-PD-1-IL-18 antibody(Fuse BioTherapeutics)) - 药物靶点：IL18R1 x PD-1_在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

抗体融合蛋白

别名

Anti-PD-1-IL-18 antibody

靶点

IL18R1 x PD-1

作用机制

IL18R1激动剂(白细胞介素18受体激动剂)、PD-1抑制剂(细胞程序性死亡-1抑制剂)

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症-

原研机构

Fuse Biotherapeutics, Inc.初创企业

在研机构

Fuse Biotherapeutics, Inc.初创企业

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Anti-PD-1-IL-18 antibody(Fuse BioTherapeutics) 相关的临床结果

登录后查看更多信息

100 项与 Anti-PD-1-IL-18 antibody(Fuse BioTherapeutics) 相关的转化医学

登录后查看更多信息

100 项与 Anti-PD-1-IL-18 antibody(Fuse BioTherapeutics) 相关的专利（医药）

登录后查看更多信息

1

项与 Anti-PD-1-IL-18 antibody(Fuse BioTherapeutics) 相关的文献（医药）

Journal of Clinical Medicine

Very Early-Onset IBD-Associated IL-18opathy Treated with an Anti-IL-18 Antibody

Article

作者: Guha, Anthea ; Hughes, Stephen M. ; Diaz-Pino, Rodrigo ; Arkwright, Peter D. ; Lopez-Castejon, Gloria ; Fagbemi, Andrew ; Wynn, Robert F.

Background/Objectives: The aetiology of inflammatory bowel disease (IBD), particularly if occurring early in childhood, is a diverse and patient-focused treatment that is required when standard therapy is ineffective. Materials and Methods: A clinical case report is presented of a child with very early-onset IBD (VEOIBD) and evidence of high serum IL-18 responding to anti-IL-18 immunotherapy. Detailed cytokine profiling was performed by ELISA and multiplex assay flow cytometry. Results: A four-year-old girl with recalcitrant VEOIBD from six weeks old due to an IL-18opathy, characterised by high blood IL-18 concentration, responded to therapy with a novel neutralising anti-IL-18 antibody (GSK1070806). After two years of hospitalisation, the child’s systemic inflammation and extensive upper and lower gastrointestinal mucosal ulceration remitted with this cytokine inhibitor, allowing the discontinuation of total parenteral nutrition and the resumption of normal oral intake and daily activities. After 18 months on regular GSK1070806, the patient remains in disease remission. Conclusions: VEOIBD can be associated with evidence of an underlying IL18opathy and responds to anti-IL-18 antibody therapy. IL-18 should be measured in patients with IBD unresponsive to conventional treatments, and, if elevated, anti-IL-18 antibody therapy should be considered as a potential therapy.

100 项与 Anti-PD-1-IL-18 antibody(Fuse BioTherapeutics) 相关的药物交易

登录后查看更多信息